Robert Barrie, a reporter with a background in neuroscience, shares the latest updates in the pharmaceutical industry. In the third quarter, Sanofi saw a big boost in sales, thanks to a 26.2% increase for their anti-inflammatory drug Dupixent. This helped Sanofi have a strong quarter, even though their vaccine sales were not as high. Galderma, another drug company, has promised to invest over $650 million in US manufacturing to meet growing demand. Roche’s CEO, Thomas Schinecker, said they are still talking with the US government about drug pricing changes, as the US president pushes for reforms. In good news for small biotech companies, early-stage funding increased by 71% in the third quarter of 2025, showing that investors are starting to support the industry again. The US Food and Drug Administration (FDA) has approved a new drug called Epioxa from Glaukos Corporation, which will help patients with a rare eye disease. The FDA has also chosen the first products for a special priority list. AstraZeneca has opened a new manufacturing facility in Texas, investing $445 million to expand their production. Sweden, known for its scientific advancements, continues to be a leader in the field. Bavarian Nordic’s board has asked shareholders to accept a better takeover offer, as the company may be sold. Kailera Therapeutics, a company that recently came out of stealth mode with nearly half a billion dollars, has secured more funding just a year later.